

Covid 19 - Acing the Treatment

Jez Hunter¹, Puskar Bura¹, Richard King², and George Thomson³

¹Royal Cornwall Hospitals NHS Trust

²Affiliation not available

³Royal Cornwall Hospital

July 19, 2021

Abstract

ACE 2 is the functional receptor that SARS-Cov-2 virus requires to enter cells and cause dysregulated inflammatory conditions that contribute towards acute lung injuries. The RAAS with its physiological surveillance and regulation system can be implicated in both harm and therapeutic benefit. The initial observational studies suggesting the discontinuation of ACE-I and ARBs have been firmly rebutted by international societies. On the contrary, these therapeutics may confer a survival benefit in Covid 19 infections. Understanding the biological plausibility of this pathway alongside the emerging therapeutic evidence may yield new modes of treatment. Such developments appear fundamentally important in the battle against the inevitable emergence of new variants and their potential to drive future waves of Covid 19 pandemics.

Hosted file

Acing the Treatment 1.4.docx available at <https://authorea.com/users/426469/articles/530994-covid-19-acing-the-treatment>